CO5660275A2 - Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 - Google Patents

Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5

Info

Publication number
CO5660275A2
CO5660275A2 CO05126935A CO05126935A CO5660275A2 CO 5660275 A2 CO5660275 A2 CO 5660275A2 CO 05126935 A CO05126935 A CO 05126935A CO 05126935 A CO05126935 A CO 05126935A CO 5660275 A2 CO5660275 A2 CO 5660275A2
Authority
CO
Colombia
Prior art keywords
inhibitor
pde5
pde4
phosphodiesterase
disease
Prior art date
Application number
CO05126935A
Other languages
English (en)
Inventor
Thorsten Dunkern
Armin Hatzelmann
Christian Schudt
Fridrich Grimminger
Hossein Ardeschir Ghofrani
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CO5660275A2 publication Critical patent/CO5660275A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- El uso combinado de un inhibidor de la PDE4 y un inhibidor de la PDE5 para la prevención o reducción del surgimiento de síntomas de una enfermedad, o el tratamiento o reducción, de la gravedad de una enfermedad en un paciente que lo necesite, en cuya enfermedad la actividad de la fosfodiesterasa 4 (PDE4) y/o fosfodiesterasa 5 (PDE5) resulta dañina.3.- Un método para la prevención o reducción del surgimiento de síntomas de una enfermedad en la que la actividad de la fosfodiesterasa 4 (PDE4) y/o fosfodiesterasa 5 (PDE5) resulta dañina, o el tratamiento o reducción, de la gravedad de una enfermedad en la que la actividad de la fosfodiesterasa 4 (PDE4) y/o fosfodiesterasa 5 (PDE5) resulta dañina, mediante la administración simultánea de una cantidad efectiva de (1) un inhibidor de la PDE4 y (2) un inhibidor de la PDE5 a un paciente que lo necesite.
CO05126935A 2003-05-22 2005-12-16 Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 CO5660275A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011609 2003-05-22

Publications (1)

Publication Number Publication Date
CO5660275A2 true CO5660275A2 (es) 2006-07-31

Family

ID=33462087

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05126935A CO5660275A2 (es) 2003-05-22 2005-12-16 Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5

Country Status (23)

Country Link
US (3) US20060094723A1 (es)
EP (1) EP1628682B1 (es)
JP (1) JP2006528229A (es)
KR (1) KR20060012004A (es)
CN (1) CN1791429A (es)
AU (1) AU2004241749B2 (es)
BR (1) BRPI0410326A (es)
CA (1) CA2525946C (es)
CO (1) CO5660275A2 (es)
EA (1) EA012279B1 (es)
EC (1) ECSP056173A (es)
GE (1) GEP20084342B (es)
IL (1) IL171306A (es)
IS (1) IS8181A (es)
MA (1) MA27855A1 (es)
MX (1) MXPA05012302A (es)
NO (1) NO333501B1 (es)
NZ (1) NZ544040A (es)
RS (1) RS52730B (es)
TN (1) TNSN05265A1 (es)
UA (1) UA83041C2 (es)
WO (1) WO2004103407A2 (es)
ZA (1) ZA200508116B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
JP2007504201A (ja) 2003-09-05 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト 真性糖尿病の治療のためのｐｄｅ４阻害剤の使用
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
ES2433661T3 (es) 2005-04-19 2013-12-12 Takeda Gmbh Roflumilast para el tratamiento de hipertensión pulmonar
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
EA032476B1 (ru) 2006-07-05 2019-06-28 Астразенека Аб ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
AU2007303846B2 (en) * 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2010013925A2 (en) * 2008-07-31 2010-02-04 Dong-A Pharmaceutical. Co., Ltd. Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
JP2014526461A (ja) * 2011-09-09 2014-10-06 エスケー ケミカルズ カンパニー，リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
EA201791271A1 (ru) * 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
US10058545B2 (en) * 2016-08-09 2018-08-28 Cipla Limited Method of treating pulmonary arterial hypertension
CN107648224A (zh) * 2017-10-31 2018-02-02 泰州中国医药城中医药研究院 一种治疗和预防心力衰竭药物及其在制药中的应用
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN108976107B (zh) * 2018-08-23 2021-03-23 南方医科大学 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
EA200300836A1 (ru) * 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4
ATE347361T1 (de) * 2001-05-25 2006-12-15 Boehringer Ingelheim Pharma Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient

Also Published As

Publication number Publication date
IL171306A (en) 2013-08-29
MA27855A1 (fr) 2006-04-03
AU2004241749B2 (en) 2010-03-25
US20120196867A1 (en) 2012-08-02
NO333501B1 (no) 2013-06-24
UA83041C2 (ru) 2008-06-10
BRPI0410326A (pt) 2006-05-23
ECSP056173A (es) 2006-04-19
NZ544040A (en) 2009-03-31
CA2525946A1 (en) 2004-12-02
NO20055941L (no) 2005-12-14
ZA200508116B (en) 2007-01-31
EP1628682A2 (en) 2006-03-01
MXPA05012302A (es) 2006-01-30
RS52730B (sr) 2013-08-30
EA200501690A1 (ru) 2006-06-30
US20060094723A1 (en) 2006-05-04
KR20060012004A (ko) 2006-02-06
RS20050858A (en) 2007-12-31
IS8181A (is) 2005-12-14
GEP20084342B (en) 2008-03-25
WO2004103407A2 (en) 2004-12-02
CN1791429A (zh) 2006-06-21
TNSN05265A1 (en) 2007-07-10
EA012279B1 (ru) 2009-08-28
CA2525946C (en) 2013-01-29
JP2006528229A (ja) 2006-12-14
US20100234382A1 (en) 2010-09-16
AU2004241749A1 (en) 2004-12-02
EP1628682B1 (en) 2013-09-25
WO2004103407A3 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
CO5660275A2 (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
AU2459402A (en) Composition
FR2869231A1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
CR9444A (es) Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes

Legal Events

Date Code Title Description
FG Application granted